 "Sun Pharma gains on patent litigation settlement with Actavis")
Shares of drug maker Sun Pharma are trading higher by nearly 2% to Rs 913 on the BSE after Ranbaxy Pharmaceuticals, its US subsidiary,and its partners Cipher Pharmaceuticals Inc. (Cipher) and Galephar Pharmaceutical Research, Inc. (Galephar) settled a patent litigation with Actavis over the generic version of Absorica, a drug used to treat acne Absorica (isotretinoin capsules).
Under the agreement, Ranbaxy and its partners along with Actavis entered into a non-exclusive pact which will permit Actavis to sell the generic version of Absorica in December 2020 which is nine months before the expiry of patent.
Earlier, Sun Pharma had made a tender offer to acquire US-based eyecare firm InSite Vision for USD 0.35 per share in cash.
The stock opened at Rs 909.90 and touched a high of Rs 915.90 on the BSE. A total of 114,802 shares changed hands on the BSE so far.
ALSO READ: Sun Pharma ends patent dispute with Actavis
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%